Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...

New CEO Nat Edington has made a stratospheric start since joining last May. The company has turnover of £50million, but he ...

DNA analysis is considered the gold standard for identifying victims of mass fatalities. But how does it work?